We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders (SMP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00873574
Recruitment Status : Completed
First Posted : April 1, 2009
Last Update Posted : March 8, 2013
Information provided by (Responsible Party):

Study Description
Brief Summary:
The main goal of the study is to progress in our understanding of the molecular basis of myeloproliferative disorders of the bone marrow (polycythemia vera, essential thrombocythemia, primary myelofibrosis). The study will focus on the genes encoding factors implicated in the JAK-STAT pathway which has an essential role in these diseases

Condition or disease Intervention/treatment
Myeloproliferative Disorders Biological: Blood samples and buccal swabs

Detailed Description:

Myeloproliferative disorders (MPD) are rare malignant diseases of the bone marrow characterized by a proliferation of differentiated blood cells during a long time and a possible transformation in an acute leukaemia.

The recent identification of a recurrent activating tyrosine kinase mutation V617F in the JAK2 gene provides a breakthrough in the understanding of the molecular mechanisms of these diseases. It can't explain nevertheless the phenotypic diversity of MPD and the occurrence of familial aggregations. The investigators have shown actually that the mutation V617F is a somatic one which is variably expressed among patients in the same family.Other somatic mutations and inherited factors, still unknown, may explain these discrepancies. JAK-STAT pathway has an essential role in non-CML MPD as was shown by the functional consequences of the V617F JAK2 mutation. Therefore, the investigators will focus our study on the genes encoding factors implicated in this signalling pathway. Two genetic approaches will be used: 1-study of known polymorphisms (SNP) of theses genes involved in the JAK-STAT pathway; 2-search of rare mutations located in specific regions (binding domain…) of candidate genes.The study is a national multicenter research based on the national network (55 centers) that the investigators have organized with the help of the French Society Of Hematology in 1998. The investigators propose to include 120 families defined by the presence of at least 2 cases of non CML MPD (WHO and PVSG criteria).The investigators have already collected 60 families (affected cases and control subject); the other 60 will be included in the next two years. In each family, only the two patients with MPD and one control will be included ( all the subjects above 18 years old). Peripheral blood samples (35ml) and buccal swabs will be collected for each subject. Hematologists and ONCOGENETICIANS will include the families, collect all the clinical and biological data and perform the collection of biological material from each subject included in the study according to approved rules.All the data will be anonymously registered on Access data base. Hematological studies will be done in the Immuno-Hematological Laboratory in Saint ANTOINE. Genetic studies will be conducted in the Genetic Department of Saint ANTOINE Hospital now transferred to Pitie-Salpetriere Hospital in Paris. The genetic study will be based on the analysis of 120 unrelated familial SMP cases (randomised) and 120 controls. The investigators will study 10 genes involved in the JAK-STAT pathway ( cytokine receptors, Janus kinases, regulatory factors).The genotyping of SNPs, selected from HAPMAP and CGEMS databases will be performed by quantitative PCR. The investigators plan to analyze 50 SNPs per subject i.e. 24000 genotypes (duplicate points). The analysis will be based on the allelic frequency comparison in the two groups using a bilateral paired t-test; 120 pairs of subjects (case control) allow to detect a 0.6 deviation standard of allelic frequency between cases and controls (alpha = 5%, beta = 10%). The search for rare mutations will be done by genomic sequencing of particular regions in candidates genes in the 120 affected cases.

Study Design

Study Type : Observational
Actual Enrollment : 234 participants
Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Molecular Study of Factors Involved in JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders
Study Start Date : September 2008
Primary Completion Date : May 2011
Study Completion Date : September 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Group/Cohort Intervention/treatment
2 patients with MPD for each family. One case for each family will be randomised ; the cohort will be of 120 patients.
Biological: Blood samples and buccal swabs
Peripheral blood samples (35 ml) and buccal swabs
1 control for each family
Biological: Blood samples and buccal swabs
Peripheral blood samples (35 ml) and buccal swabs

Outcome Measures

Primary Outcome Measures :
  1. Allelic frequency comparison between the 2 cohorts [ Time Frame: At the inclusion visit ]

Secondary Outcome Measures :
  1. Undescribed gene mutations. [ Time Frame: At the inclusion visit ]

Biospecimen Retention:   Samples With DNA
Peripheral blood samples (35 ml) and buccal swabs

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Population of familial patients with MPD and controls

Inclusion Criteria:

  • Patients affected with polycythemia vera, essential thrombocythemia or primary myelofibrosis
  • Familial cases
  • Subjects above 18 years old
  • Non affected controls

Exclusion Criteria:

  • patients with chronic myeloid leukaemia
  • subjects under 18 years old
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00873574

Department of Hematology, Hospital Saint Antoine
Paris, France, 75012
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Principal Investigator: Albert NAJMAN, MD PhD Assistance Publique - Hôpitaux de Paris
More Information

Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT00873574     History of Changes
Other Study ID Numbers: AOR 07014
First Posted: April 1, 2009    Key Record Dates
Last Update Posted: March 8, 2013
Last Verified: March 2013

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Familial myeloproliferative disorders

Additional relevant MeSH terms:
Myeloproliferative Disorders
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases